SARS CoV-2 coronavirus / Covid-19 (No tin foil hat silliness please)

WI_Red

Redcafes Most Rested
Joined
May 20, 2018
Messages
12,038
Location
No longer in WI
Supports
Atlanta United
Moderna vaccine Phase I results just been published in NEJM. Look pretty good too. Bumped their share price 16%.
I saw that article. I am going to tamp down my enthusiasm, but it does look promising. I think this would be the first mRNA vaccine ever approved, right? The concept of mRNA vaccines is hella cool and eliminates some of the concerns with attenuated virus or protein antigen based vaccines. Keeping my fingers crossed.
 

Lennon7

nipple flasher and door destroyer
Joined
May 8, 2013
Messages
10,473
Location
M5
I’m interested to know what life is like in most of China, or previously sketchy areas that quickly got the virus under control like parts of Japan and S. Korea. Has life returned to normal for you yet? Are you able to move around freely, go to bars and restaurants and use trains/transport as you did before? Or are there still big measures in place, measures that we should still be following in the UK?
 

Wibble

In Gadus Speramus
Staff
Joined
Jun 15, 2000
Messages
88,602
Location
Centreback
I saw that article. I am going to tamp down my enthusiasm, but it does look promising. I think this would be the first mRNA vaccine ever approved, right? The concept of mRNA vaccines is hella cool and eliminates some of the concerns with attenuated virus or protein antigen based vaccines. Keeping my fingers crossed.
https://www.phgfoundation.org/briefing/rna-vaccines
 

berbatrick

Renaissance Man
Scout
Joined
Oct 22, 2010
Messages
21,539
I saw that article. I am going to tamp down my enthusiasm, but it does look promising. I think this would be the first mRNA vaccine ever approved, right? The concept of mRNA vaccines is hella cool and eliminates some of the concerns with attenuated virus or protein antigen based vaccines. Keeping my fingers crossed.
my old PI worked on targeted RNA therapies and he quoted eye-watering prices for a single dose. i'm not 100% sure why the manufacturing is so difficult - it cn't be just making the sequence itself - but i wonder if that will change for the massive mass production this might require.
 

Wibble

In Gadus Speramus
Staff
Joined
Jun 15, 2000
Messages
88,602
Location
Centreback
my old PI worked on targeted RNA therapies and he quoted eye-watering prices for a single dose. i'm not 100% sure why the manufacturing is so difficult - it cn't be just making the sequence itself - but i wonder if that will change for the massive mass production this might require.
I believe that rna vaccines are theoretically cheaper and faster to produce when scaled up. I'd guess the high price is because we have never done this yet.
 

WI_Red

Redcafes Most Rested
Joined
May 20, 2018
Messages
12,038
Location
No longer in WI
Supports
Atlanta United
I believe that rna vaccines are theoretically cheaper and faster to produce when scaled up. I'd guess the high price is because we have never done this yet.
I don’t even think production will be an issue. I look at the price of custom oligo production when I got to grad school in 2002, it’s not even close to the same.

I think the real issue is going to be transport and stabilization. mRNA is crazy unstable, and shipping doses at -80 or in storage solutions chock full of ribonuclease inhibitors is probably a no go. I am not sure if any of the commercial room temp storage option (like RNAstable) are usable.

Long story short there are reasons why rna vaccines have yet to make their debut even though they off advantages. Nothing like a pandemic induced dumping of cash to speed it along.
 

lynchie

Full Member
Joined
Dec 9, 2006
Messages
7,065
Kinda looking forward to the emerging theories as to why all these people are dying in Texas, Florida, etc, given the virus doesn't exist.
 

lynchie

Full Member
Joined
Dec 9, 2006
Messages
7,065
"The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified."
Sounds good! Is this the same sort of approach the Imperial vaccine is based on as well?
 

JPRouve

can't stop thinking about balls - NOT deflategate
Scout
Joined
Jan 31, 2014
Messages
65,354
Location
France
Kinda looking forward to the emerging theories as to why all these people are dying in Texas, Florida, etc, given the virus doesn't exist.
"The US health system is so bad that people easily die of a common cold."

That's not even outlandish.
 

Smores

Full Member
Joined
May 18, 2011
Messages
25,496
How is an enclosed office environment different from a shop environment?

Coronavirus: Matt Hancock rejects face coverings for offices

https://www.bbc.co.uk/news/uk-53415030
Offices should be putting in place social distancing measures is the main reason i think. There's a big difference between wearing one for a brief shop visit where social distancing isn't possible and all day at your desk when you're already 2 metres apart.
 

lynchie

Full Member
Joined
Dec 9, 2006
Messages
7,065
"The US health system is so bad that people easily die of a common cold."

That's not even outlandish.
But saying the US health system is substantially worse at dealing with the common cold this year, in a number of red states, doesn't really give the message they're looking for - that Democrats are making this up to affect the election.

Like, it basically has to be that Dems are killing people?
 

JPRouve

can't stop thinking about balls - NOT deflategate
Scout
Joined
Jan 31, 2014
Messages
65,354
Location
France
But saying the US health system is substantially worse at dealing with the common cold this year, in a number of red states, doesn't really give the message they're looking for - that Democrats are making this up to affect the election.

Like, it basically has to be that Dems are killing people?
I know. But there is no way out of it, either the virus is real or the US health system is shoddy or both. The Trumprites don't realize that they are not helping their cause with their nonsense.
 

decorativeed

Full Member
Joined
Oct 19, 2009
Messages
12,328
Location
Tameside

the replies.. good lord!
The absolute egos on these people that the whole world would shut down their economies for months just to target republicans and their president. A group who make up less than 1% of the world's population.
 

Smores

Full Member
Joined
May 18, 2011
Messages
25,496
I know. But there is no way out of it, either the virus is real or the US health system is shoddy or both. The Trumprites don't realize that they are not helping their cause with their nonsense.
"If it wasn't for Obamacare and the Dems blocking Trumps wonder drugs we'd have saved them all".

It'll be some bollocks like that but with a lot more capitals.
 

decorativeed

Full Member
Joined
Oct 19, 2009
Messages
12,328
Location
Tameside
But saying the US health system is substantially worse at dealing with the common cold this year, in a number of red states, doesn't really give the message they're looking for - that Democrats are making this up to affect the election.

Like, it basically has to be that Dems are killing people?
They have already had to come up with a change of narrative to explain why it's not only happening in 'Dem states' now. Mental gymnastics worthy of olympic medals.
 

acnumber9

Full Member
Joined
Jun 21, 2006
Messages
22,253
Offices should be putting in place social distancing measures is the main reason i think. There's a big difference between wearing one for a brief shop visit where social distancing isn't possible and all day at your desk when you're already 2 metres apart.
There is big difference and it’s not one that supports wearing them in shops over wearing them in offices.
 

Phil

Full Member
Joined
Aug 15, 2003
Messages
11,371
You come here looking for genuine information about the virus, which you do get and is great, but you leave wondering how America is so broken.
 

RedFish

Full Member
Joined
May 26, 2014
Messages
7,973
Location
Su Mudaerji Fan Club
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

Looks like a vaccine developed in the US works. Phase1 open label trial

New England Journal of Medicine

ORIGINAL ARTICLE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
List of authors.
  • Lisa A. Jackson, M.D., M.P.H.,
  • Evan J. Anderson, M.D.,
  • Nadine G. Rouphael,
July 14, 2020
DOI: 10.1056/NEJMoa2022483

Abstract
BACKGROUND

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.
METHODS
We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.
RESULTS
After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti–S-2P antibody geometric mean titer [GMT], 40,227 in the 25-μg group, 109,209 in the 100-μg group, and 213,526 in the 250-μg group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-μg dose group reported one or more severe adverse events.
CONCLUSIONS
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461. opens in new tab)
 

Carolina Red

Moderator
Staff
Joined
Nov 7, 2015
Messages
36,295
Location
South Carolina
https://www.nejm.org/doi/full/10.1056/NEJMoa2022483

Looks like a vaccine developed in the US works. Phase1 open label trial

New England Journal of Medicine

ORIGINAL ARTICLE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
List of authors.
  • Lisa A. Jackson, M.D., M.P.H.,
  • Evan J. Anderson, M.D.,
  • Nadine G. Rouphael,
July 14, 2020
DOI: 10.1056/NEJMoa2022483

Abstract
BACKGROUND

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine. The candidate vaccine mRNA-1273 encodes the stabilized prefusion SARS-CoV-2 spike protein.
METHODS
We conducted a phase 1, dose-escalation, open-label trial including 45 healthy adults, 18 to 55 years of age, who received two vaccinations, 28 days apart, with mRNA-1273 in a dose of 25 μg, 100 μg, or 250 μg. There were 15 participants in each dose group.
RESULTS
After the first vaccination, antibody responses were higher with higher dose (day 29 enzyme-linked immunosorbent assay anti–S-2P antibody geometric mean titer [GMT], 40,227 in the 25-μg group, 109,209 in the 100-μg group, and 213,526 in the 250-μg group). After the second vaccination, the titers increased (day 57 GMT, 299,751, 782,719, and 1,192,154, respectively). After the second vaccination, serum-neutralizing activity was detected by two methods in all participants evaluated, with values generally similar to those in the upper half of the distribution of a panel of control convalescent serum specimens. Solicited adverse events that occurred in more than half the participants included fatigue, chills, headache, myalgia, and pain at the injection site. Systemic adverse events were more common after the second vaccination, particularly with the highest dose, and three participants (21%) in the 250-μg dose group reported one or more severe adverse events.
CONCLUSIONS
The mRNA-1273 vaccine induced anti–SARS-CoV-2 immune responses in all participants, and no trial-limiting safety concerns were identified. These findings support further development of this vaccine. (Funded by the National Institute of Allergy and Infectious Diseases and others; mRNA-1273 ClinicalTrials.gov number, NCT04283461. opens in new tab)
I’m torn between excitement and the knowledge that a lot of Americans will either refuse to have it or possibly won’t be able to afford it.

Excited for the rest of y’all though.
 

Pexbo

Winner of the 'I'm not reading that' medal.
Joined
Jun 2, 2009
Messages
68,413
Location
Brizzle
Supports
Big Days
I’m torn between excitement and the knowledge that a lot of Americans will either refuse to have it or possibly won’t be able to afford it.

Excited for the rest of y’all though.
Its sad for the children who will miss out because of moronic parents but I have little to no sympathy for adults who will succumb to their own ignorance.